Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: A pilot study

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 4, 2006, Pages 256-261

  Spirou, Athanasia ^a   Rizos, Evangelos ^a   Liberopoulos, Evangelos N ^a   Kolaitis, Nikolaos ^b   Achimastos, Apostolos ^c   Tselepis, Alexandros D ^d   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Barnidipine; Cholesterol; Fibrinogen; Hypertension; Isoprostane; Lipoprotein associated phospholipase A2; Metabolic parameters; Paraoxonase; Plasminogen activator inhibitor 1

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALPHA 2 ANTIPLASMIN; APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE 1; ELECTROLYTE; FIBRINOGEN; GLUCOSE; ISOPROSTANE; MEPIRODIPINE; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG EFFECT; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; GLUCOSE HOMEOSTASIS; HUMAN; INTERVENTION STUDY; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OXIDATIVE STRESS; PRIORITY JOURNAL; SAMPLE SIZE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANTIHYPERTENSIVE AGENTS; ARYLDIALKYLPHOSPHATASE; BLOOD COAGULATION; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; ELECTROLYTES; FEMALE; FIBRINOLYSIS; GREECE; HUMANS; HYPERTENSION; ISOPROSTANES; KIDNEY FUNCTION TESTS; LIPIDS; MALE; MIDDLE AGED; NIFEDIPINE; OXIDATIVE STRESS; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845597072     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406296108     Document Type: Article

References (34)

1. Liau CS. Barnidipine: a new calcium channel blocker for hypertension treatment. Expert Rev Cardiovasc Ther. 2005 ; 3: 207-213.
2. Malhotra HS, Plosker GL. Barnidipine. Drugs. 2001 ; 61: 989-996.
3. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005 ; 46: 1978-1985.
4. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004 ; 109 (23 suppl 1). III20 - III26.
5. Fruchart JC, Nierman MC, Stroes ES, et al. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004 ; 109 (23 suppl 1). III15 - III19.
6. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999 ; 34: 943-949.
7. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003 ; 284: R893 - R912.
8. Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004 ; 24: 580-589.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 ; 352: 1685-1695.
11. Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers. 2005 ; 10 (suppl 1). S24 - S29.
12. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001 ; 37: 541-546.
13. Laragh JH. Two forms of vasoconstriction in systemic hypertension. Am J Cardiol. 1987 ; 60: 82G - 93G.
14. Krier JD, Rodriguez-Porcel M, Best PJ, et al. Vascular responses in vivo to 8-epi PGF(2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol. 2002 ; 283: R303 - R308.
15. Ganafa AA, Walton M, Eatman D, et al. Amlodipine attenuates oxidative stress-induced hypertension. Am J Hypertens. 2004 ; 17: 743-748.
16. Zhou MS, Jaimes EA, Raij L. Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. Am J Hypertens. 2004 ; 17: 167-171.
17. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemiaassociated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1208-1212.
18. Eisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase: implication for atherosclerosis. Biochem Pharmacol. 2003 ; 66: 2069-2073.
19. Chait A, Han CY, Oram JF, et al. The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res. 2005 ; 46: 389-403.
20. Rizos E, Tambaki AP, Gazi I, et al. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005 ; 72: 203-209.
21. Tambaki AP, Rizos E, Tsimihodimos V, et al. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther. 2004 ; 9: 91-95.
22. Kosegawa I, Inaba M, Morita T, et al. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Clin Exp Hypertens. 1998 ; 20: 751-761.
23. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005 ; 28: 209-214.
24. Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther. 2004 ; 26: 1228-1236.
25. Koyama Y, Kodama K, Suzuki M, et al. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens. 2002 ; 15: 927-931.
26. Dahlöf B, Sever PS, Poulter NR, et al, ASCOT Investigators. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 ; 366: 895-906.
27. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens. 2004 ; 22: 1453-1458.
28. Whelton PK, Barzilay J, Cushman WC, et al, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005 ; 165: 1401-1409.
29. Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets. 2006 ; 7: 211-228.
30. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation. 2002 ; 105: 457-461.
31. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005 ; 27: 578-587.
32. Ridderstrale W, Ulfhammer E, Jern S, et al. Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. Hypertension. 2006 ; 47: 686-691.
33. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT study. J Am Soc Nephrol. 2004 ; 15 (suppl 1). S51 - S54.
34. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med. 2004 ; 164: 2459-2464.